Follow RSS for latest reports on this topicSteatohepatitis - Market Research and Reports

Nonalcoholic Steatohepatitis Therapeutics in Asia-Pacific Markets to 2024 - Launch of NASH-Specific Premium Products and Rising Prevalence to Drive the Market [Report Updated: 03-12-2018]

Nonalcoholic Steatohepatitis Therapeutics in Asia-Pacific Markets to 2024 - Launch of NASH-Specific Premium Products and Rising Prevalence to Drive the MarketSummaryNon-alcoholic steatohepatitis (NASH) is the severe form of non-alcoholic fatty liver disease (NAFLD), characterized by a buildup of fat in the liver. Globally, the NAFLD prevalence rate is estimated to be around 25% and a significant p...Read More >>>

Published:
2018-12-03

Published by: GBI Research

Prices Starting From:
$4995

Competitor Landscape: Non-alcoholic Steatohepatitis (NASH) [Report Updated: 30-11-2018]

Competitor Landscape: Non-alcoholic Steatohepatitis (NASH)SummarySociable Pharma’s ‘Treatment Landscape’ contains evaluations of ongoing development activities within the NASH market, analysis of current & potential future product positioning, and forecast approval dates (by quarter) for candidates in Phase II development, or higher - - Executive Summary: Contains analysis of key market even...Read More >>>

Published:
2018-11-30

Published by: Global Data

Prices Starting From:
$6400

Non-Alcoholic Steatohepatitis (NASH): Dynamic Market Forecast to 2026 [Report Updated: 28-09-2018]

Non-Alcoholic Steatohepatitis (NASH): Dynamic Market Forecast to 2026SummaryNon-alcoholic steatohepatitis (NASH) is a common, often clinically silent liver disease characterized by the presence of a fatty, inflamed, and damaged liver. It resembles alcoholic liver disease but occurs in people who drink little or no alcohol, and is a highly progressed form of non-alcoholic fatty liver disease (NAFLD...Read More >>>

Published:
2018-09-28

Published by: Global Data

Prices Starting From:
$8495

Steatohepatitis Global Clinical Trials Review, H2, 2018 [Report Updated: 31-08-2018]

Steatohepatitis Global Clinical Trials Review, H2, 2018SummaryGlobalData's clinical trial report, “Steatohepatitis Global Clinical Trials Review, H2, 2018 provides an overview of Steatohepatitis clinical trials scenario. This report provides top line data relating to the clinical trials on Steatohepatitis. Report includes an overview of trial numbers and their average enrollment in top countrie...Read More >>>

Published:
2018-08-31

Published by: Global Data

Prices Starting From:
$2500

Non-Alcoholic Steatohepatitis (NASH) - Pipeline Review, H2 2018 [Report Updated: 17-07-2018]

Non-Alcoholic Steatohepatitis (NASH) - Pipeline Review, H2 2018SummaryGlobal Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Non-Alcoholic Steatohepatitis (NASH) - Pipeline Review, H2 2018, provides an overview of the Non-Alcoholic Steatohepatitis (NASH) (Gastrointestinal) pipeline landscape.Non-alcoholic steatohepatitis (NASH) is liver inflammation caused by a buildup...Read More >>>

Published:
2018-07-17

Published by: Global Markets Direct

Prices Starting From:
$2000

Non-Alcoholic Steatohepatitis (NASH) Global Clinical Trials Review, H1, 2018 [Report Updated: 31-03-2018]

Non-Alcoholic Steatohepatitis (NASH) Global Clinical Trials Review, H1, 2018SummaryGlobalData's clinical trial report, “Non-Alcoholic Steatohepatitis (NASH) Global Clinical Trials Review, H1, 2018 provides an overview of Non-Alcoholic Steatohepatitis (NASH) clinical trials scenario. This report provides top line data relating to the clinical trials on Non-Alcoholic Steatohepatitis (NASH). Repor...Read More >>>

Published:
2018-03-31

Published by: Global Data

Prices Starting From:
$2500

Non Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH) Drug Development Pipeline Review, 2018 [Report Updated: 22-03-2018]

Non Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH) Drug Development Pipeline Review, 2018SummaryThis report provides an overview of the non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) pipeline landscape. The report provides comprehensive information on the therapeutics under development and key players active in this space, and als...Read More >>>

Published:
2018-03-22

Published by: GBI Research

Prices Starting From:
$3995

Non-Alcoholic Steatohepatitis (NASH) - Pipeline Insight, 2018 [Report Updated: 14-02-2018]

Non-Alcoholic Steatohepatitis (NASH) - Pipeline Insight, 2018” report by DelveInsight offers comprehensive Insight of the pipeline (under development) therapeutics scenario and growth prospects across Non-Alcoholic Steatohepatitis (NASH) development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with comple...Read More >>>

Published:
2018-02-14

Published by: Delve Insight

Prices Starting From:
$2000

Nonalcoholic Steatohepatitis (NASH) - Market Insight, Epidemiology and Market Forecast - 2027 [Report Updated: 14-02-2018]

DelveInsight's Nonalcoholic Steatohepatitis (NASH) - Market Insight, Epidemiology and Market Forecast - 2027 report provides a detailed analysis of the Nonalcoholic Steatohepatitis (NASH) epidemiology and market outlook for the 7MM.Markets Covered• United States• EU5 (Germany, France, Italy, Spain, and the United Kingdom)• JapanStudy Period: 2016-2027Nonalcoholic Steatohepatitis (NASH) ...Read More >>>

Published:
2018-02-14

Published by: Delve Insight

Prices Starting From:
$6250

Global and Chinese NASH (Non-alcoholic Steatohepatitis) Biomarkers Industry, 2017 Market Research Report [Report Updated: 15-12-2017]

The 'Global and Chinese NASH (Non-alcoholic Steatohepatitis) Biomarkers Industry, 2012-2022 Market Research Report' is a professional and in-depth study on the current state of the global NASH (Non-alcoholic Steatohepatitis) Biomarkers industry with a focus on the Chinese market. The report provides key statistics on the market status of the NASH (Non-alcoholic Steatohepatitis) Biomarkers manufact...Read More >>>

Published:
2017-12-15

Published by: Prof Research

Prices Starting From:
$3000

Nonalcoholic Steatohepatitis (NASH) - Market Insights, Epidemiology and Market Forecast – 2027 [Report Updated: 01-09-2017]

DelveInsight’s ‘Nonalcoholic Steatohepatitis (NASH)- Market Insights, Epidemiology and Market Forecast-2027’ report provides a disease overview of the Nonalcoholic Steatohepatitis (NASH) along with the epidemiology and the market scenario in the 7MM – United States, EU5 (Germany, France, Spain Italy , United Kingdom) and Japan. The Report covers the therapeutics market revenue, treatment p...Read More >>>

Published:
2017-09-01

Published by: Delve Insight

Prices Starting From:
$5750

Non-Alcoholic Steatohepatitis (NASH) - Pipeline Insight, 2017 [Report Updated: 31-07-2017]

DelveInsight’s, “Non-Alcoholic Steatohepatitis (NASH)-Pipeline Insights, 2017”, report provides comprehensive insights of the ongoing therapeutic research and development across Non-Alcoholic Steatohepatitis (NASH). The report provides a complete understanding of the pipeline activities covering all clinical, pre-clinical and discovery stage products. A comparative pipeline therapeutics asse...Read More >>>

Published:
2017-07-31

Published by: Delve Insight

Prices Starting From:
$2000

Global Fatty Liver Disease Drugs Market By Type (ALD, NAFLD), By Stages of ALD and NAFLD, By Region, By Country: Opportunities and Forecast (2017-2022) - By ALD Stages (Alcoholic Steatosis, Alcoholic Steatohepatitis), By NAFLD Stages (Steatosis, NASH) [Report Updated: 25-07-2017]

Executive SummaryA comprehensive research report created through extensive primary research (inputs from industry experts, companies, stakeholders) and secondary research, the report aims to present the analysis of Global Fatty Liver Disease Market on the basis of Type (Alcoholic Fatty Liver Disease or ALD), Non Alcoholic Fatty Liver Disease or NAFLD), By Alcoholic Fatty Liver Stages (Alcoholic S...Read More >>>

Published:
2017-07-25

Published by: Azoth Analytics

Prices Starting From:
$2400

Non-Alcoholic Steatohepatitis (NASH) - Pipeline Review, H2 2017 [Report Updated: 11-07-2017]

Non-Alcoholic Steatohepatitis (NASH) - Pipeline Review, H2 2017SummaryGlobal Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Non-Alcoholic Steatohepatitis (NASH) - Pipeline Review, H2 2017, provides an overview of the Non-Alcoholic Steatohepatitis (NASH) (Gastrointestinal) pipeline landscape.Non-alcoholic steatohepatitis (NASH) is liver inflammation caused by a buildup...Read More >>>

Published:
2017-07-11

Published by: Global Markets Direct

Prices Starting From:
$2000

Non-Alcoholic Steatohepatitis - Pipeline Review, H1 2017 [Report Updated: 28-02-2017]

Non-Alcoholic Steatohepatitis - Pipeline Review, H1 2017SummaryGlobal Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Non-Alcoholic Steatohepatitis - Pipeline Review, H1 2017, provides an overview of the Non-Alcoholic Steatohepatitis (Gastrointestinal) pipeline landscape.Non-alcoholic steatohepatitis (NASH) is liver inflammation caused by a buildup of fat in the liver....Read More >>>

Published:
2017-02-28

Published by: Global Markets Direct

Prices Starting From:
$2000

EpiCast Report: Non-Alcoholic Steatohepatitis - Epidemiology Forecast to 2025

EpiCast Report: Non-Alcoholic Steatohepatitis - Epidemiology Forecast to 2025SummaryNon-alcoholic steatohepatitis (NASH) is a common, often clinically silent liver disease characterized by the presence of steatosis (fatty liver), in addition to liver inflammation and damage. Unlike alcoholic liver disease, NASH occurs in those who drink little or no alcohol. NASH usually presents with few or no sy...Read More >>>

Published:
2016-12-01

Published by: Global Data

Prices Starting From:
$3995

Non-Alcoholic Steatohepatitis Global Clinical Trials Review, H2, 2016

Non-Alcoholic Steatohepatitis Global Clinical Trials Review, H2, 2016SummaryGlobalData's clinical trial report, “Non-Alcoholic Steatohepatitis Global Clinical Trials Review, H2, 2016 provides an overview of Non-Alcoholic Steatohepatitis clinical trials scenario. This report provides top line data relating to the clinical trials on Non-Alcoholic Steatohepatitis. Report includes an overview of tr...Read More >>>

Published:
2016-11-30

Published by: Global Data

Prices Starting From:
$2500

Steatohepatitis Global Clinical Trials Review, H2, 2016

Steatohepatitis Global Clinical Trials Review, H2, 2016SummaryGlobalData's clinical trial report, “Steatohepatitis Global Clinical Trials Review, H2, 2016 provides an overview of Steatohepatitis clinical trials scenario. This report provides top line data relating to the clinical trials on Steatohepatitis. Report includes an overview of trial numbers and their average enrollment in top countrie...Read More >>>

Published:
2016-11-30

Published by: Global Data

Prices Starting From:
$2500

Nonalcoholic Steatohepatitis (NASH): KOL Insight [Report Updated: 01-05-2016]

Who will benefit most from huge opportunities in NASH treatment?The first new NASH therapy is due soon: but is it safe and effective enough? How happy are KOLs with the plethora of current trials and endpoints? Which is more appealing: tackling early signs or advanced stages? With no cure in sight and issues around diagnosis, long-term safety and cost all still being hotly debated-clearly there is...Read More >>>

Published:
2016-05-01

Published by: FirstWord Pharma

Prices Starting From:
$7900

Steatohepatitis Global Clinical Trials Review, H2, 2015

Steatohepatitis Global Clinical Trials Review, H2, 2015SummaryGlobalData's clinical trial report, “Steatohepatitis Global Clinical Trials Review, H2, 2015 provides an overview of Steatohepatitis clinical trials scenario. This report provides top line data relating to the clinical trials on Steatohepatitis. Report includes an overview of trial numbers and their average enrollment in top countrie...Read More >>>

Published:
2015-12-16

Published by: Global Data

Prices Starting From:
$2500

Non-Alcoholic SteatoHepatitis (NASH): An Analysis of Disease Prevalence, Drugs in development, Regulatory guidelines and Market opportunity in Various Geographies

Within the oral mucosal cavity, the buccal region offers an attractive route of administration for systemic drug delivery. The mucosa has a rich blood supply and it is relatively permeable. The buccal mucosa offers several advantages for controlled drug delivery for extended periods of time. The mucosa is well supplied with both vascular and lymphatic drainage and first-pass metabolism in the liv...Read More >>>

Published:
2015-12-01

Published by: MP Advisors

Prices Starting From:
$3500

Global NASH (Non –Alcoholics Steatohepatitis) Market: Trends, Opportunities and Forecasts (2015-2030) (By Region, By Drugs – Off Label & Special Treatment Drugs, Aramachol, Clinical Pipeline, GR-MD-02, GFT 505 Market) [Report Updated: 01-12-2015]

Executive SummaryProgressive numbers of Liver disorders along with rise in obesity will fuel the demand for NASH DrugsThe Global NASH Market is growing at a moderate rate over last five years on account of rising number of obesity among young population. NASH (non-alcoholic steatohepatitis) is a large, un-tapped market with no FDA approved therapeutics. Antioxidants, anti-diabetic medications, ant...Read More >>>

Published:
2015-12-01

Published by: Azoth Analytics

Prices Starting From:
$2000

Non-Alcoholic Steatohepatitis Global Clinical Trials Review, H2, 2015

Non-Alcoholic Steatohepatitis Global Clinical Trials Review, H2, 2015SummaryGlobalData's clinical trial report, “Non-Alcoholic Steatohepatitis Global Clinical Trials Review, H2, 2015 provides an overview of Non-Alcoholic Steatohepatitis clinical trials scenario. This report provides top line data relating to the clinical trials on Non-Alcoholic Steatohepatitis. Report includes an overview of tr...Read More >>>

Published:
2015-11-30

Published by: Global Data

Prices Starting From:
$2500

Nonalcoholic Steatohepatitis: KOL Insight

IntroductionWhy This Report is Essential Expect a revolution in the treatment of nonalcoholic steatohepatitis (NASH) as a number of new therapies compete to become the first approved treatment for a disease that has high unmet clinical need. Nonalcoholic Steatohepatitis: KOL Insight reveals the critical views of US and European KOLs whose insights hold key lessons for pharma. Gain insights on prod...Read More >>>

Published:
2015-03-01

Published by: FirstWord Pharma

Prices Starting From:
$7900